56.26
前日終値:
$55.15
開ける:
$55.61
24時間の取引高:
681.18K
Relative Volume:
0.80
時価総額:
$3.49B
収益:
$45.48M
当期純損益:
$169.95M
株価収益率:
21.47
EPS:
2.62
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
+1.88%
1か月 パフォーマンス:
+1.02%
6か月 パフォーマンス:
+48.09%
1年 パフォーマンス:
+39.67%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PTGX
Protagonist Therapeutics Inc
|
56.26 | 3.42B | 45.48M | 169.95M | 230.85M | 2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-17 | 開始されました | Citigroup | Buy |
2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
2024-12-06 | 開始されました | Goldman | Neutral |
2024-11-05 | 開始されました | Wedbush | Outperform |
2024-09-24 | 開始されました | TD Cowen | Buy |
2024-09-09 | 開始されました | Truist | Buy |
2023-10-30 | 開始されました | CapitalOne | Overweight |
2023-05-25 | 再開されました | Jefferies | Buy |
2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
2022-02-11 | 開始されました | BTIG Research | Buy |
2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
2021-05-24 | 開始されました | Northland Capital | Outperform |
2021-01-06 | 開始されました | JP Morgan | Overweight |
2020-12-16 | 開始されました | Piper Sandler | Overweight |
2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
2020-07-15 | 開始されました | Jefferies | Buy |
2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
2019-07-08 | 開始されました | H.C. Wainwright | Buy |
2019-05-09 | アップグレード | Stifel | Hold → Buy |
2018-12-06 | 開始されました | Nomura | Buy |
2018-01-29 | 開始されました | Stifel | Buy |
2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Protagonist therapeutics CEO Patel sells $570k in stock By Investing.com - Investing.com India
What is the dividend policy of Protagonist Therapeutics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
What are Protagonist Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - jammulinksnews.com
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - jammulinksnews.com
What institutional investors are buying Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - jammulinksnews.com
Is Protagonist Therapeutics Inc. a growth stock or a value stockGame-changing returns - jammulinksnews.com
Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayShort Squeeze Radar - metal.it
Does Protagonist Therapeutics Inc. stock pay reliable dividendsFree Consultation - metal.it
Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis - MSN
Protagonist Therapeutics Inc. Stock Analysis and ForecastExponentially increasing returns - PrintWeekIndia
What analysts say about Protagonist Therapeutics Inc. stockHigh-performance investment picks - PrintWeekIndia
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Newport Daily News
CEO’s Major Stock Sale Shakes Up Protagonist Therapeutics! - TipRanks
Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India
Protagonist Therapeutics CEO Patel sells $2.88 million in shares - Investing.com
What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional
Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):